Drug Topics - September 22, 2008 - (Page 5) DRUG TOPICS 5 Of Interest to Pharmacists in brand products will be going off patent, which will provide significant opportunities for generics companies. At a time when Congress and state legislatures are looking for ways to make health care more affordable, generics are the right choice. the market share. For those manufacturers who are new to the market, this will be a major challenge. When you look at the generics manufacturing industry, there is more and more migration to India to take advantage of the manufacturing skills and talents available within that country. Without a doubt, you’re going to see more mergers and acquisitions in the Indian pharmaceutical market. It is anticipated that we are going to begin to see finished goods come from China within the next 12 to 24 months. They will be viewed similarly to how the Indian manufacturers were perceived in the latter part of the 1990s. Ranbaxy was one of the first Indian companies to come to the United States. We spent the first few years establishing the Ranbaxy name and credibility in the marketplace before the first product was ever sold. Any new foreign-based manufacturers, such as those located in China, are going to have to do the same or something similar. Between 2009 and 2011, a number of blockbuster products are coming off patent. Based on current Bill Winter market dynamics, these products will be launched by a firstto-file manufacturer or multiple first-to-file companies, along with an authorized generic. Afterward, you will have another group, possibly as many as seven to 11 manufacturers coming to market on Day 181. From that point onward, price erosion will seriously undermine the value of the product. Bill Winter Vice President of Trade Sales Ranbaxy Pharmaceuticals Inc. Consolidation in the generic manufacturing industry is well underway, and I feel that the pace will continue at a rapid rate in the near future. Consolidation in the retail sector has also been underway for some time now. Chains and wholesalers are now quite large, with 10 to 12 buyers accounting for approximately 80 to 85 percent of http://www.watson.com
Table of Contents Feed for the Digital Edition of Drug Topics - September 22, 2008 Drug Topics - September 22, 2008 Contents Generics Executives Look Ahead to 2009 Congress Still Working on Biologic Generics Bill Drug Topics - September 22, 2008 Drug Topics - September 22, 2008 - Contents (Page 1) Drug Topics - September 22, 2008 - Contents (Page 2) Drug Topics - September 22, 2008 - Generics Executives Look Ahead to 2009 (Page 3) Drug Topics - September 22, 2008 - Generics Executives Look Ahead to 2009 (Page 4) Drug Topics - September 22, 2008 - Generics Executives Look Ahead to 2009 (Page 5) Drug Topics - September 22, 2008 - Congress Still Working on Biologic Generics Bill (Page 6)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.